Website, in het bijzonder R&D pipeline, werd aangepast :
GLPG0974 - inflammation
GLPG0974 is an orally available small molecule that inhibits GPR43 (G-protein coupled receptor), also known as FFAR2 (free fatty acid receptor 2). It was identified by Galapagos as playing a key role in inflammation and has shown potent inhibition of neutrophil migration, one of the critical cell types in inflammatory processes. Overactivity of neutrophils is a cause of tissue damage in illnesses such as inflammatory bowel disease, and this anti-inflammatory mechanism may provide for a novel treatment approach. GLPG0974 has successfully passed single dose animal safety evaluation and will be the first inhibitor of GPR43 to be evaluated clinically.
The primary endpoints of the first-in-human trial for GLPG0974 will be to determine the pharmacokinetics and to evaluate biomarker effects of this candidate drug. In addition, the safety and tolerability of a wide dose range will be evaluated. The placebo-controlled, double-blind, single ascending dose study is being conducted in 36 healthy human volunteers in Belgium over the coming months. It follows the design for exploratory single dose trials, as supported by guidelines that EMEA and the FDA designed to boost innovation in drug discovery and development.